How big is the protein inhibitors market today, and what are its future growth expectations?
The protein inhibitors market size has grown strongly in recent years. It will grow from $80.99 billion in 2024 to $88.74 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to drug discovery, drug development, cancer treatment, regulatory approvals.
The protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $125.26 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to precision medicine, immunotherapy, drug combinations, aging population. Major trends in the forecast period include data sharing and collaboration, sustainability and ESG, personalized medicine, and adaptive clinical trials.
Get Your Free Sample of The Global Protein Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3429&type=smp
What have been the primary factors driving the protein inhibitors market’s growth?
The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. For instance, in June 2024, according to the National Health Service, a UK-based publicly funded healthcare system in England, there were 3,615,330 people registered with a GP who were found to have non-diabetic hyperglycemia—also known as pre-diabetes—in 2023, compared to 3,065,825 in 2022—an increase of almost a fifth (18%). Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for growth of the protein inhibitors market.
What are the key segments within the protein inhibitors market?
The protein inhibitors market covered in this report is segmented –
1) By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products
2) By Application: Oncology, Inflammatory Diseases, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies
Subsegments:
1) By Protein Kinase Inhibitors: Selective Kinase Inhibitors, Non-selective Kinase Inhibitors, Small Molecule Kinase Inhibitors, Biologic Kinase Inhibitors
2) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Conjugated Monoclonal Antibodies
3) By Other Products: Peptide Inhibitors, Protein Degradation Technologies, Small Molecule Inhibitors, Combination Therapy Products
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report
Which key players are shaping the protein inhibitors market?
Major companies operating in the protein inhibitors market include Bayer AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Novartis International AG, GlaxoSmithKline plc, Pfizer Inc., Boehringer Ingelheim International GmbH, Abbott Laboratories, Amgen Inc., Baxter International Inc., Merck & Co. Inc., Interprotein Corporation, AbbVie Inc., Bristol Myers Squibb Company, Galapagos NV, Priovant Therapeutics Inc., Tempus Labs Inc., ReCode Therapeutics Inc., Satellite Bio Inc., Ambagon Therapeutics Inc., Biogen Inc., Eli Lilly and Company, Gilead Sciences Inc., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Inc., Lonza Group AG, Catalent Inc., Thermo Fisher Scientific Inc., Charles River Laboratories International Inc., WuXi AppTec Co. Ltd.
How will industry trends affect the trajectory of the protein inhibitors market?
The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market shortly. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibody therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibodies was $96,731 for 34 monoclonal antibody indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibody indication combinations yet accounted for more than 85% of those priced at $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergies, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth.
How do regional factors impact the protein inhibitors market, and which region is the largest contributor?
North America was the largest region in the protein inhibitors market in 2024. The regions covered in the protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Protein Inhibitors Market Report 2025 Offer?
The protein inhibitors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3429
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
